Hormonal Acne: Drugs That Cause It, Drugs That Treat It, and What Your Breakouts Are Telling You

What Is Hormonal Acne and Why Does It Happen to Women More?

Hormonal acne is acne whose timing, location, or severity is governed primarily by fluctuations in sex hormones, particularly androgens and progesterone. It is not a separate diagnosis in the ICD-10 system, but clinicians recognize a distinct female pattern: inflammatory papules and nodules clustered along the jawline, chin, and lower cheeks that worsen predictably with the menstrual cycle, pregnancy, perimenopause, or hormonal medication changes.

Women are disproportionately affected compared with men in adulthood. Data from a 2008 survey of 1,013 adults found that acne persisted into adulthood in approximately 50% of women in their 20s, 35% in their 30s, and 26% in their 40s, rates considerably higher than age-matched men. The biology behind this gap matters clinically.

The Androgen Connection

Androgen receptors sit on sebaceous glands throughout the skin. When testosterone or its more potent derivative dihydrotestosterone (DHT) binds those receptors, sebaceous glands enlarge and produce more sebum. That excess oil, combined with abnormal keratinization of the follicular lining, creates the anaerobic environment where Cutibacterium acnes proliferates and triggers inflammation.

In women, the main androgen sources are the ovaries and adrenal glands. Any condition that raises free androgens, including polycystic ovary syndrome (PCOS), late-onset congenital adrenal hyperplasia, or an androgen-secreting tumor, can worsen acne markedly. PCOS alone accounts for a significant proportion of adult female acne: one study found that between 27% and 37% of women referred to dermatology for acne had biochemical hyperandrogenism.

The Progesterone and Insulin Connection

Progesterone is pro-sebaceous. It rises sharply in the luteal phase (days 15-28 of a typical cycle), which explains why many women notice flares in the week before their period. Progesterone also has mild androgenic activity, particularly in its synthetic forms (certain progestins), which compounds the effect.

Insulin and IGF-1 amplify androgen signaling in the skin. Research published in the Journal of the Academy of Nutrition and Dietetics linked high-glycemic-load diets and dairy consumption to acne severity, a finding that has particular relevance for women with PCOS, who often carry insulin resistance even at a normal body weight.

Drugs That Cause or Worsen Hormonal Acne

Several common medications disrupt the androgen-estrogen or insulin balance enough to trigger or worsen acne. If your breakouts started or worsened after starting a new medication, the drug deserves scrutiny.

Progestins With High Androgenic Activity

Not all progestins are created equal. Older, 19-nortestosterone-derived progestins, including levonorgestrel, norgestrel, and norethindrone, carry measurable androgenic activity at the androgen receptor. Women using contraceptives or hormone therapy formulations containing these progestins may notice new or worsened acne, particularly along the jawline.

By contrast, third- and fourth-generation progestins such as desogestrel, norgestimate, and drospirenone have low or anti-androgenic activity, which is why the combined oral contraceptives (COCs) containing them are used therapeutically for acne. ACOG Clinical Consensus guidance on hormonal contraception notes this clinically relevant difference in androgenic potency across progestin classes.

The progestogen-only pill (mini-pill), particularly norethindrone-containing formulations, and the hormonal IUD (levonorgestrel-releasing) occasionally worsen acne in androgen-sensitive women, though the systemic levonorgestrel dose from an IUD is very low and most users do not experience this effect.

Corticosteroids

Systemic and topical corticosteroids can produce a specific acne variant called steroid acne, characterized by monomorphic papulopustules on the trunk and upper back rather than the typical hormonal distribution. The mechanism is direct stimulation of sebaceous glands and follicular epithelium. Long-term inhaled corticosteroids at high doses have also been reported to cause acne in susceptible women, though this is less common than with oral formulations.

Lithium and Anticonvulsants

Lithium is among the medications most consistently linked to acne exacerbation in controlled observations. The mechanism is thought to involve increased neutrophil chemotaxis and altered follicular keratinization. Valproate, used in bipolar disorder and epilepsy, raises testosterone and insulin levels in some women and has been linked to PCOS-like features including acne and hirsutism, particularly in women of reproductive age.

Anabolic Steroids and Testosterone Therapy

Exogenous androgens are the most direct acne trigger. Women using testosterone for low libido (HSDD), as part of gender-affirming hormone therapy, or illicitly for athletic performance should expect acne as a dose-dependent side effect. The Endocrine Society's clinical practice guideline on testosterone therapy in women recommends monitoring for androgenic side effects including acne when testosterone is used.

Other Notable Offenders

• Danazol (used for endometriosis): strongly androgenic, almost universally causes acne.
• High-dose progesterone used in ART cycles: can flare acne transiently.
• Epidermal growth factor receptor (EGFR) inhibitors (cancer therapy): cause a distinct acneiform eruption that is not hormonally mediated but is frequently misclassified.

Drugs That Treat Hormonal Acne in Women

The treatment options differ meaningfully by life stage and reproductive intention. This section goes through each major drug class with the specifics you need.

Combined Oral Contraceptives (COCs)

COCs work against acne through two mechanisms: suppressing ovarian androgen production and raising sex hormone-binding globulin (SHBG), which binds free testosterone and reduces its availability to sebaceous glands.

Three COC formulations carry FDA approval specifically for acne: norgestimate/ethinyl estradiol (Ortho Tri-Cyclen), norethindrone acetate/ethinyl estradiol/ferrous fumarate (Estrostep Fe), and drospirenone/ethinyl estradiol/levomefolate (Beyaz). A 2012 Cochrane review of 31 trials found that COCs reduced total acne lesion counts significantly compared with placebo, with drospirenone-containing pills showing slightly stronger anti-androgenic effects.

COCs are a logical first-line choice for women who also want contraception, have PCOS with acne, or have cyclically worsening acne tied to the luteal phase.

Who may not be suitable: Women with a personal or family history of estrogen-sensitive thrombosis, migraine with aura, uncontrolled hypertension, or those over 35 who smoke.

Spironolactone

Spironolactone is an aldosterone antagonist that also blocks androgen receptors and reduces 5-alpha-reductase activity in the skin. It is not FDA-approved specifically for acne, but it has decades of off-label use and is now embedded in major dermatology guidelines as a standard of care for adult female acne.

The SAHA syndrome (seborrhea, acne, hirsutism, alopecia), which reflects androgen excess across multiple tissues, responds particularly well to spironolactone. A 2023 randomized controlled trial published in the BMJ found that spironolactone 50-200 mg daily reduced acne lesion counts significantly more than placebo over 24 weeks in women with mild-to-moderate acne, with 65% of participants achieving treatment success at the 200 mg dose.

Typical dosing starts at 50 mg daily and is titrated to 100-200 mg depending on response and tolerability. Side effects include menstrual irregularity (often managed by combining with a COC), breast tenderness, and, at higher doses, mild diuresis.

Life-stage nuance: Spironolactone is a reasonable option at almost any adult reproductive life stage outside of pregnancy. In perimenopause, when acne often re-emerges alongside falling estrogen and relatively higher androgen activity, spironolactone alone or combined with low-dose estrogen addresses both issues.

Isotretinoin

Oral isotretinoin (formerly Accutane, now generic) is the only acne treatment that can produce long-term remission, defined as clear or near-clear skin for at least one year off therapy, in a substantial proportion of patients. It works by inducing apoptosis in sebaceous gland cells, reducing gland size by up to 90%.

A 2021 analysis in JAMA Dermatology found cumulative remission rates of approximately 85% after a single course in patients with severe nodular acne. Women with hormonal acne may require longer courses or repeat courses compared with men, possibly because the hormonal drive persists.

Dosing is weight-based, typically 0.5-1 mg/kg/day, cumulative target 120-150 mg/kg. Lower doses (0.25-0.5 mg/kg/day) have been studied in adult women specifically and show comparable efficacy with fewer mucocutaneous side effects over longer treatment durations.

Pregnancy and lactation: isotretinoin is absolutely contraindicated. See the dedicated section below for full details.

Topical Anti-Androgens: Clascoterone

Clascoterone (Winlevi) cream 1% is the first topical androgen receptor antagonist approved by the FDA, in 2020, for acne in patients 12 and older. Because it acts locally at the skin's androgen receptor without meaningful systemic absorption, it avoids the systemic anti-androgenic effects of spironolactone.

Phase 3 trial data published in the Journal of the American Academy of Dermatology showed statistically significant reductions in both inflammatory and non-inflammatory lesion counts compared with vehicle at 12 weeks. Clascoterone fills an important gap: it gives women who cannot or do not want systemic therapy (for example, those planning pregnancy soon or breastfeeding) a hormonally targeted topical option.

Oral Antibiotics: A Note on Their Role

Doxycycline and minocycline reduce C. Acnes colonization and have anti-inflammatory properties. They are not anti-androgenic and should not be the sole long-term treatment for hormonally driven acne. Guidelines from the American Academy of Dermatology (via NCBI) recommend limiting oral antibiotic courses to three to four months when possible and always pairing them with a topical retinoid to reduce resistance selection pressure. In women with clear hormonal acne patterns, antibiotics alone without hormonal therapy represent incomplete treatment.

Pregnancy, Lactation, and Contraception: What You Must Know

This section is required reading for any woman of reproductive age using or considering acne medications.

Isotretinoin: Strictly Contraindicated in Pregnancy

Isotretinoin is a Category X teratogen with a risk of major congenital anomalies exceeding 20-35% in exposed pregnancies. Documented abnormalities include craniofacial defects, cardiac malformations, thymic aplasia, and central nervous system anomalies. The drug is also associated with spontaneous abortion.

Because of this, the FDA requires enrollment in the iPLEDGE program for every prescriber, pharmacy, and patient. Women of childbearing potential must use two simultaneous forms of contraception starting one month before, during, and for one month after completing isotretinoin. Monthly pregnancy testing is mandatory.

Isotretinoin passes into breast milk; breastfeeding is contraindicated during treatment.

Spironolactone: Avoid in Pregnancy

Spironolactone is not an established human teratogen at the level of isotretinoin, but animal studies demonstrate feminization of male fetuses at doses producing plasma levels comparable to those used clinically. The FDA label warns against use in pregnancy. Most dermatologists and gynecologists recommend reliable contraception for any sexually active woman taking spironolactone for acne. It should be discontinued as soon as a pregnancy is confirmed. Spironolactone is generally considered incompatible with breastfeeding due to transfer into breast milk.

Combined Oral Contraceptives in Pregnancy

COCs should be stopped as soon as pregnancy is confirmed. They are not associated with structural fetal anomalies when inadvertently continued in early pregnancy, but continuation serves no purpose. COCs are compatible with breastfeeding at low-dose progestin-only formulations, but combined estrogen-progestin pills may suppress milk supply, particularly in the first six weeks postpartum.

Safe Options During Pregnancy and Lactation

Acne often flares in the first trimester due to rising hCG stimulating sebaceous activity, and again postpartum as estrogen drops. Safe topical options during pregnancy include azelaic acid 15-20% (Pregnancy Category B), topical erythromycin, and benzoyl peroxide. Topical clindamycin is widely used and considered low-risk. Topical retinoids (tretinoin, adapalene) are generally avoided during pregnancy due to theoretical concerns, even though systemic absorption is minimal.

Clascoterone's safety in pregnancy has not been established. Given its androgenic mechanism, caution is warranted until more data exist.

Hormonal Acne by Life Stage

Reproductive Years (Ages 18-40)

Cyclic acne that worsens in the luteal phase points directly to progesterone and androgen flux. A COC containing drospirenone or norgestimate is often the cleanest single intervention: it treats the acne and provides contraception. Spironolactone added to a COC is the combination most commonly used in specialist practice for moderate-to-severe adult female acne.

Trying to Conceive

This is the most constrained situation. Isotretinoin and spironolactone must be stopped before attempting conception. Clascoterone or azelaic acid are the only hormonally targeted options with acceptable profiles. Oral antibiotics for short courses are acceptable but should not be the main strategy.

Perimenopause (Ages 40s-50s)

Perimenopausal acne is a genuinely underserved topic with almost no dedicated trial data. The hormonal mechanism is distinct from adolescent acne: estradiol declines erratically, reducing SHBG and unmasking androgens that were previously bound. The result is acne that women describe as "coming back after decades" along the jawline, often accompanied by oiliness and hirsutism.

Spironolactone at 50-100 mg is the most logical targeted treatment at this stage. Low-dose combined hormone therapy containing a low-androgenic progestogen (micronized progesterone or dydrogesterone) may also improve acne by restoring SHBG. Isotretinoin remains an option for severe cases, provided contraception is in place until menopause is confirmed by 12 consecutive months of amenorrhea.

Post-Menopause

New-onset acne in a post-menopausal woman not on hormone therapy warrants investigation for androgen excess, including adrenal tumors and ovarian hyperthecosis. Post-menopausal women on testosterone therapy for HSDD may develop acne as a dose-dependent side effect. Spironolactone works well in this group with no contraceptive requirement needed.

How Hormonal Acne Is Diagnosed

Hormonal acne does not have a single laboratory test. Diagnosis is primarily clinical, based on pattern recognition.

Clinical Pattern

A clinician will look for the characteristic lower-face distribution, the cyclic relationship to the menstrual cycle, a history of worsening with known androgenic triggers, and the presence of other androgen-excess signs such as hirsutism, scalp hair thinning (female pattern hair loss), or irregular cycles.

Laboratory Workup

Routine bloodwork is not required for typical adult female acne. However, when acne is severe, sudden in onset, resistant to standard therapy, or accompanied by hirsutism, menstrual irregularity, or scalp hair loss, a targeted panel is appropriate. This typically includes:

• Free and total testosterone
• DHEAS (dehydroepiandrosterone sulfate)
• LH and FSH ratio (elevated in PCOS)
• Fasting insulin and glucose
• 17-hydroxyprogesterone (to exclude congenital adrenal hyperplasia)

The American Academy of Dermatology's acne guidelines do not mandate labs for mild-to-moderate adult female acne, but endocrine evaluation is recommended when signs of systemic androgen excess are present.

When to See a Specialist

See a dermatologist or gynecologist if your acne is nodular, leaving scars, not responding to two adequate topical regimens, or accompanied by signs of androgen excess. See an endocrinologist or reproductive endocrinologist if PCOS or adrenal disease is suspected.

Who This Is Right For, and Who Should Think Carefully

Good Candidates for Hormonal Treatment

• Women with cyclic acne worsening in the week before a period.
• Women with PCOS whose acne is part of a broader androgen-excess picture.
• Women who have failed two or more topical regimens without hormonal therapy.
• Perimenopausal women with new or worsening jawline acne.
• Women who want acne treatment that also provides contraception.

Women Who Need a Modified Approach

• Anyone actively trying to conceive: avoid spironolactone and isotretinoin entirely. Discuss clascoterone and azelaic acid.
• Women with a history of breast cancer or estrogen-sensitive conditions: COCs may be contraindicated; spironolactone is generally acceptable.
• Women with renal insufficiency: spironolactone raises potassium and should be used cautiously or avoided.
• Women on lithium or valproate for psychiatric conditions: discuss with your prescriber before adding spironolactone, as both affect electrolytes.
• Breastfeeding women: topical options only. Clascoterone data are insufficient; azelaic acid is the preferred hormonally relevant topical.

The Evidence Gap: What We Still Don't Know

Women have been systematically under-enrolled in acne trials, particularly before 2015. Most of the foundational isotretinoin dosing data come from mixed-sex or male-predominant cohorts. The result is that weight-based dosing recommendations may not fully account for female-specific pharmacokinetics, including the effect of body fat percentage on isotretinoin distribution.

A 2019 analysis in the British Journal of Dermatology noted that women with hormonal acne who received isotretinoin had higher relapse rates than men, a finding that has been attributed to the ongoing hormonal drive rather than inadequate dosing, but this has not been formally tested in a sex-stratified RCT.

The perimenopausal acne space is nearly a research desert. Virtually no randomized data exist on spironolactone specifically in perimenopausal acne, and the optimal hormonal therapy formulation for this population has not been studied in dedicated acne trials. What exists is extrapolated from reproductive-age data, which may not map cleanly onto a cohort with different estrogen and androgen dynamics.